Science and research
Publications
A complete overview of the papers in which we have published the results of our scientific work. They appear in respected international journals — each entry links to its record in the Web of Science.
57 papersPublished in international journals
Among them Cancers, Genes, Gastroenterology, Anticancer Research and Electrophoresis.
1Whole Tumor Heterogeneity Topography (WTHT)—A New Approach for Assessment of Intratumor Mutational Heterogeneity in Colorectal Adenomas 2Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer 3Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC 4Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis 5Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma 6Combination of Circulating Tumour DNA and 18F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study 7Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)- A Helicobacter-opposite point 8Associations between the occurrence of the ACTN3 R577X, ACE I/D, BDKRB2 +9/-9 polymorphisms and anaerobic performance among a group of elite fencers 9Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response 10Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer 11Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA 12Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors 13Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC 14Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery 15The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature 16Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis 17Longitudinal molecular characterization of endoscopic specimens from colorectal lesions 18Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib 19The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy 20Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene 21Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib 22Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC 23Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers 24High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib 25Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation 26Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy 27MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis 28The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC 29Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib 30EUS-Guided Biopsies for Molecular Testing of Pancreatic Cancer: Optimization of Experimental Parameters for DNA and miRNA Extraction and Analysis 31Genetic Testing in the Management of Relatives of Patients with Hypertrophic Cardiomyopathy 32Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence 33Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease 34Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients 35Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice 36Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy 37The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer 38Erlotinib in the treatment of advanced squamous cell NSCLC 39Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC 40Utility of Cell-free Tumour DNA for Post-surgical Follow-up of Colorectal Cancer Patients 41Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis 42Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy 43Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patients with Advanced Disease 44Circulating Free Tumor DNA in Patient Plasma is a Near-Perfect Marker for Metastatic Spread of Colorectal Cancer: A Study on 165 Patients Undergoing Surgical Treatment 45Extraordinary Response to Erlotinib Therapy in a Patient with Lung Adenocarcinoma Exhibiting KRAS Mutation and EGFR Amplification 46A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA 47Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy 48Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors 49Assembly of a large Y-STR haplotype database for the Czech population and investigation of its substructure 50Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy 51Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status 52Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer 53Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer 54Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M 55Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer 56Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections 57Multicapillary electrophoresis of unlabeled DNA fragments with high-sensitive laser-induced fluorescence detection by counter-current migration of intercalation dye